MLICM
CPRX

Metropolitan Life Insurance Company (MetLife)’s Catalyst Pharmaceutical CPRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,867
Closed -$93.5K – 493
2024
Q1 		$93.5K Buy
5,867
+21
+0.4% +$316 ﹤0.01% 1081
2023
Q4 		$98.3K Hold
5,846
– – ﹤0.01% 1093
2023
Q3 		$68.3K Buy
5,846
+333
+6% +$4.45K ﹤0.01% 1219
2023
Q2 		$74.1K Hold
5,513
– – ﹤0.01% 1190
2023
Q1 		$91.4K Sell
5,513
-781
-12% -$12.9K ﹤0.01% 1032
2022
Q4 		$117K Hold
6,294
– – 0.01% 971
2022
Q3 		$80.8K Hold
6,294
– – ﹤0.01% 1148
2022
Q2 		$44.1K Hold
6,294
– – ﹤0.01% 1583
2022
Q1 		$52.2K Sell
6,294
-17,282
-73% -$122K ﹤0.01% 1563
2021
Q4 		$160K Sell
23,576
-2,831
-11% -$18.6K ﹤0.01% 2178
2021
Q3 		$140K Buy
26,407
+4,109
+18% +$22.5K ﹤0.01% 2325
2021
Q2 		$128K Sell
22,298
-8,020
-26% -$41.4K ﹤0.01% 2457
2021
Q1 		$140K Buy
30,318
+2,792
+10% +$11.1K ﹤0.01% 2253
2020
Q4 		$91.9K Sell
27,526
-438
-2% -$1.47K ﹤0.01% 2393
2020
Q3 		$83.1K Sell
27,964
-3,124
-10% -$12.2K ﹤0.01% 2320
2020
Q2 		$144K Buy
31,088
+10,959
+54% +$49.2K ﹤0.01% 2032
2020
Q1 		$77.5K Buy
20,129
+4,079
+25% +$16.7K ﹤0.01% 2192
2019
Q4 		$60.2K Sell
16,050
-19,713
-55% -$92.2K ﹤0.01% 2482
2019
Q3 		$190K Buy
35,763
+7,482
+26% +$39.9K ﹤0.01% 1914
2019
Q2 		$109K Hold
28,281
– – ﹤0.01% 2259
2019
Q1 		$144K Buy
28,281
+1,028
+4% +$3.02K ﹤0.01% 2107
2018
Q4 		$52.3K Hold
27,253
– – ﹤0.01% 2505
2018
Q3 		$103K Hold
27,253
– – ﹤0.01% 2438
2018
Q2 		$85K Buy
27,253
+6,885
+34% +$20.9K ﹤0.01% 2391
2018
Q1 		$48.7K Sell
20,368
-1,836
-8% -$6.1K ﹤0.01% 2443
2017
Q4 		$87K Buy
+22,204
New +$73.4K ﹤0.01% 2383
2016
Q1 		– Sell
-55,663
Closed -$136K – 2510
2015
Q4 		$136K Buy
55,663
+8,218
+17% +$23.5K ﹤0.01% 2467
2015
Q3 		$142K Sell
47,445
-9,426
-17% -$40.7K ﹤0.01% 2504
2015
Q2 		$235K Buy
+56,871
New +$227K ﹤0.01% 2290

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CPRX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Catalyst Pharmaceutical (CPRX) in Q2 2024, closing a stake of 5,867 shares — an estimated $93.5K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CPRX in Q2 2015 and held it in 29 quarters. The position peaked at $235K in Q2 2015. 271 funds tracked by Wall St. Rank hold CPRX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Catalyst Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 5,867 Catalyst Pharmaceutical shares in Q2 2024, an estimated $93.5K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Catalyst Pharmaceutical in Q2 2015 and held it in 29 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Catalyst Pharmaceutical position peaked at $235K in Q2 2015.
  • 271 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.